Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

JBIO stock hub

Jade Biosciences, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

JBIOis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.3B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

JBIO

In the news

Latest news · JBIO

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROEn/a

P25 -105.6P50 -46.5P75 -3.1

ROICn/a

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All JBIO market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

161

Groups with data

Currency

USD

Showing 161 of 161 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0000947559
Company name	Jade Biosciences, Inc.
Country	United States
Country code	US
Cusip	008064206
Employees	55
Enterprise value	$963.2M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US0080642061
Last refreshed	2026-05-10
Market cap	$1.3B
Market cap category	Small-Cap
Price	$25.81
Price currency	USD
Sector	Healthcare
Sic	6021
Symbol	JBIO
Website	https://jadebiosciences.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-8.03%
FCF yield	-7.87%
P/B ratio	4.3x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-102.3M
Net Income Growth Years	0%
Profit Per Employee	$-1.9M
ROCE	-44.96

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	178.92%
EPS Growth Quarters	7
EPS Growth Years	2
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$319.4M
Cash	$311.3M
Current Assets	$318.5M
Current Liabilities	$22.3M
Debt	$679,000
Debt Equity	$0
Equity	$296.5M
Interest Coverage	-37.11
Liabilities	$23M
Long Term Assets	$916,000
Long Term Liabilities	$679,000
Net Cash	$310.6M
Net Cash By Market Cap	$24.38
Net Debt Equity	$-1.05
Tangible Book Value	$296.5M
Tangible Book Value Per Share	$6.01

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	14.29
Net Working Capital	$-15.1M
Quick ratio	13.96
Working Capital	$296.2M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Dividend Growth Years	1%
Dividend per share	$0
Dividend Years	1
Dividend Yield	0%
Last Dividend	$2.4

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	178.73%
200-day SMA	12.95
50-day SMA	18.23
50-day SMA vs 200-day SMA	50over200
All Time High	28
All Time High Change	-7.82%
All Time High Date	2026-04-27
All Time Low	6.57
All Time Low Change	293.15%
All Time Low Date	2025-06-13
ATR	1.86
Beta1y	1.29
Beta2y	1.29
Ch YTD	67.27
High	26.61
High52	28
High52 Date	2026-04-27
High52ch	-7.82%
Low	23.82
Low52	6.57
Low52 Date	2025-06-13
Low52ch	293.15%
Ma50ch	41.6%
Price vs 200-day SMA	99.24%
RSI	64.74
RSI Monthly	0
RSI Weekly	76.96
Sharpe ratio	1.64x
Sortino ratio	2.75
Tr YTD	67.27
Tr1m	57.76%
Tr1w	6.52%
Tr3m	68.47%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	5
Analyst Count Top	3
Analyst Price Target Top	$35.67
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.49
Operating Income	$-133.6M
Price target	$31.2
Price Target Change	$20.88
Price Target Change Top	$38.2

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	32,728,661%
Float Percent	66.32%
Shares Insiders	0.36%
Shares Institutions	77.52%
Shares Out	49,353,223
Shares Qo Q	7.01%
Short Float	9.35%
Short Ratio	4.51
Short Shares	6.2

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-125.2M
Average Volume	685,705.5x
Bv Per Share	6.01
CAPEX	$-196,000
Ch1m	57.76
Ch1w	6.52
Ch1y	178.7
Ch3m	68.47
Ch6m	180.8
Change	6.56%
Change From Open	8.35
Close	24.22
Days Gap	-1.65
Depreciation Amortization	35,000
Dollar Volume	18,002,294.3
Earnings Date	2026-05-07
Earnings Time	amc
EBIT	$-133.6M
EPS	$-2.27
F Score	1
FCF	$-100.2M
FCF EV Yield	-10.4x
FCF Per Share	$-2.03
Financing CF	360,673,000
Fiscal Year End	December
Founded	2,024
Income Tax	$74,000
Investing CF	-255,476,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2025-03-03
Ma150	14.71
Ma150ch	75.45%
Ma20	23.66
Ma20ch	9.09%
Net CF	5,156,000
Next Earnings Date	2026-08-12
Open	23.82
Optionable	Yes
Payment Date	2025-04-28
Position In Range	71.33
Ppne	847,000
Price Date	2026-05-08
Ptbv Ratio	4.3
Relative Volume	1.02x
Share Based Comp	24,991,000
Tr6m	180.85%
Us State	Massachusetts
Volume	697,493

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does JBIO pay a dividend?

Capital-return profile for this ticker.

Performance

JBIO stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns JBIO?

Insider, institutional, and short-interest positioning.

Institutional ownership

+77.5%

Float: +66.3% of shares outstanding

Insider ownership

+0.4%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

JBIO momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

64.7

Neutral momentum band

Price vs 200-day MA

+99.2%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

1.64

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About JBIO

Hub-level FAQ points readers to the deeper analysis pages.

What is the current JBIO stock rating?

Jade Biosciences, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full JBIO analysis?

The full report lives at /stocks/JBIO/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for JBIO?

The latest report frames JBIO around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the JBIO page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.